<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 14, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712983</url>
  </required_header>
  <id_info>
    <org_study_id>CTBM100G2202</org_study_id>
    <secondary_id>2015-003040-39</secondary_id>
    <nct_id>NCT02712983</nct_id>
  </id_info>
  <brief_title>Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection</brief_title>
  <acronym>iBEST-1</acronym>
  <official_title>A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen's University Belfast, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Antwerp, BE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan, IT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomedica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital Cambridge, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton Hospital Trust, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to support the selection of a safe and tolerable tobramycin&#xD;
      inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.&#xD;
      aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa&#xD;
      colonization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a blinded, randomized, dose and regimen finding trial utilizing a three treatment&#xD;
      cohort design where active TIP and TIP/Placebo cyclical (3 capsules o.d [Cohort A], 5&#xD;
      capsules o.d. [Cohort B] or 4 capsules b.i.d. [Cohort C]) versus Placebo were administered&#xD;
      for a total of 112 days.&#xD;
&#xD;
      Novartis decided to close the recruitment of new subjects into this study earlier than&#xD;
      scheduled. Subjects who had a signed informed consent form and entered screening by&#xD;
      10-Sep-2018 still participated in the study. The latest possible randomization was on&#xD;
      08-Oct-2018. All subjects enrolled in the study (107 enrolled subjects out of 180 planned)&#xD;
      continued as planned through to their last scheduled visit. The early recruitment halt of the&#xD;
      study was not due to safety or lack of efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Actual">March 20, 2019</completion_date>
  <primary_completion_date type="Actual">March 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)</measure>
    <time_frame>Baseline (Visit 101/Day 1), Visit 102 (Day 8), Visit 103 (Day 29)</time_frame>
    <description>Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. Change was determined using the formula = (Post-baseline value - baseline value). If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. Only values for all morphotypes presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Post-baseline Visit in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)</measure>
    <time_frame>Baseline (Visit 101/Day 1), Visit 104 (Day 57), Visit 105 (Day 85), Visit 106 (Day 113), End of Treatment (EOT), Visit 201 (Day 141), Visit 202 (Day 169)</time_frame>
    <description>Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. Change was determined using the formula = (Post-baseline value - baseline value). If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. Only values for all morphotypes are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Onset of Pulmonary Exacerbation by Exacerbation Category</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The time to first onset of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization. Participants were censored at the time of completion of study or early discontinuation if they did not have a pulmonary exacerbation during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Pulmonary Exacerbation by Exacerbation Category</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The duration of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure Adjusted Rate of Pulmonary Exacerbations (PE) Over the Entire Study Period</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The exposure adjusted rate of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization. The Exposure adjusted rate = (Number of pulmonary exacerbations reported during the study period) / (sum of study duration in days for all participants/ 365.25). Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Pulmonary Exacerbation by Exacerbation Category</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>Pulmonary exacerbations are defined as events requiring antibiotic therapy AND for which at least 3 of the following 6 symptoms, signs, or findings were present outside of normal variation: 1. Increased sputum volume, or change in viscosity/consistency or purulence for more than 24 hours; 2. Increased shortness of breath at rest or on exercise for more than 24 hours; 3. Increased cough for more than 24 hours; 4. Fever of ≥38° Celsius within the last 24 hours; 5. Increased malaise/fatigue/lethargy for more than 24 hours; 6. A reduction in forced expiratory volume in the first second of expiration (FEV1) or forced vital capacity (FVC) of least 10% from screening.&#xD;
Participants were categorized as: a) Overall, b) Category 1: treated with oral antibiotics only and c) Category 2: treated with parenteral Antibiotics and/or requiring hospitalization.&#xD;
Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Permanently Discontinued Study Drug Due to Pulmonary Exacerbation</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The percentage of participants who permanently discontinued study drug due to pulmonary exacerbation compared to placebo was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Permanent Study Drug Discontinuation Due to Pulmonary Exacerbation</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The time to permanent study drug discontinuation due to Pulmonary exacerbation. Participants were censored at the time of last contact if they did not permanently discontinue study drug due to pulmonary exacerbation requiring during the study period. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use (Overall, Oral, and Parenteral) of Anti-pseudomonal Antibiotics Usage</measure>
    <time_frame>From Baseline (Visit 101/Day 1) up to approximately Day 173</time_frame>
    <description>The time to first use of anti-pseudomonal antibiotics administered compared to placebo was analyzed. Participants were censored at the time of last contact if they did not have anti-pseudomonal antibiotics over the entire study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Anti-pseudomonal Antibiotics</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The percentage of participants requiring anti-pseudomonal antibiotics compared to placebo was analyzed. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Anti-pseudomonal Antibiotics Usage</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The total number of days of new anti-pseudomonal antibiotic use compared to placebo was analyzed. Only descriptive analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Hospitalization Due to Serious Respiratory-related Adverse Events</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The percentage of participants requiring hospitalization due to serious respiratory-related adverse events (other than those regularly scheduled hospitalization that were planned prior to study start) was analyzed to define severity of pulmonary exacerbations compared to placebo. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization Due to Serious Respiratory-related Adverse Events</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The duration of hospitalization due to serious respiratory-related adverse events (other than those regularly scheduled hospitalization that were planned prior to study start) was analyzed to define severity of pulmonary exacerbations compared to placebo. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalization Due to Serious Respiratory-related Adverse Events</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>The number of hospitalization due to serious respiratory-related AEs was analyzed to define severity of pulmonary exacerbations compared to placebo. Respiratory related adverse events were identified using the AEs captured under system organ class 'Respiratory, thoracic and mediastinal disorders' and 'Infections and infestations'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Hospitalization Due to Serious Respiratory-related Adverse Events</measure>
    <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
    <description>Time to first hospitalization due to serious respiratory-related AEs was analyzed to define severity of pulmonary exacerbations compared to placebo. Participants were censored at the time of last contact if they did not have a hospitalization due to serious respiratory-related adverse events over the entire study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Tobramycin Concentration</measure>
    <time_frame>Baseline (Visit 101/Day 1), Visit 102 (Day 8) and Visits 103 (Day 29): 0-1 hours and 1-2 hours post-dose.</time_frame>
    <description>The serum pharmacokinetic (PK) properties of tobramycin were assessed by evaluating tobramycin concentrations in serum collected from the non-cystic fibrosis bronchiectasis population post administration of o.d. or b.i.d. doses of TIP. Serum specimens for PK tobramycin concentration were assessed at Visit 101 (Day 1/start of treatment) 0 to 1 and 1 to 2 hours post-dose and Visit 102 (Day 8) 0 to 1 and 1 to 2 hours post-dose. Prior to protocol amendment #2, PK samples were assessed on Visits 103 (Day 29) rather than Visit 102. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Tobramycin Concentration</measure>
    <time_frame>Baseline (Visit 101/Day 1): 0-1 hours and 1-2 hours post-dose; Visit 102 (Day 8):0-2 hours and 5-6 hours post-dose; Visits 103 (Day 29): 5 to 6 hours post-dose, Visit 104 (Day 57) and Visit 105 (Day 85): 3-4 hours post-dose.</time_frame>
    <description>The sputum pharmacokinetic (PK) properties of tobramycin were assessed by evaluating tobramycin concentrations in sputum collected from the non-cystic fibrosis bronchiectasis population post administration of o.d. or b.i.d. doses of TIP. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Physical Functioning</measure>
    <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
    <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Role Functioning</measure>
    <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
    <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Vitality</measure>
    <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
    <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Emotional Functioning</measure>
    <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
    <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Social Functioning</measure>
    <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
    <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Treatment Burden</measure>
    <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
    <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Health Perceptions</measure>
    <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
    <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Respiratory Symptoms</measure>
    <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
    <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Non-cystic Fibrosis Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Cohort A (3 capsules o.d.): TIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (3 capsules o.d.): TIP/PBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (3 capsules o.d.): PBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A (3 capsules o.d.): Inhaled placebo (PBO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (5 capsules o.d.): TIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (5 capsules o.d.): TIP/PBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (5 capsules o.d.): PBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort B (5 capsules o.d.): inhaled placebo (PBO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C (4 capsules b.i.d.): TIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C (4 capsules b.i.d.): TIP/PBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C (4 capsules b.i.d.): PBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP</intervention_name>
    <description>TIP dose regimen</description>
    <arm_group_label>Cohort A (3 capsules o.d.): TIP</arm_group_label>
    <arm_group_label>Cohort B (5 capsules o.d.): TIP</arm_group_label>
    <arm_group_label>Cohort C (4 capsules b.i.d.): TIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP and placebo</intervention_name>
    <description>TIP and inhaled placebo dose regimen</description>
    <arm_group_label>Cohort A (3 capsules o.d.): TIP/PBO</arm_group_label>
    <arm_group_label>Cohort B (5 capsules o.d.): TIP/PBO</arm_group_label>
    <arm_group_label>Cohort C (4 capsules b.i.d.): TIP/PBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo dose regimen</description>
    <arm_group_label>Cohort A (3 capsules o.d.): PBO</arm_group_label>
    <arm_group_label>Cohort B (5 capsules o.d.): PBO</arm_group_label>
    <arm_group_label>Cohort C (4 capsules b.i.d.): PBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          -  Male and female patients of ≥ 18 years of age at screening (Visit 1).&#xD;
&#xD;
          -  Proven diagnosis of non-CF BE as documented by computed tomography or high-resolution&#xD;
             computed tomography&#xD;
&#xD;
          -  At least 2 or more exacerbations treated with oral antibiotics OR 1 or more&#xD;
             exacerbation requiring intravenous antibiotic treatment within 12 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  FEV1 ≥ 30% predicted at screening (Visit 1).&#xD;
&#xD;
          -  P. aeruginosa, must be documented in a respiratory sample at least 1 time within 12&#xD;
             months and also present in the expectorated sputum culture at Visit 1.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of cystic fibrosis.&#xD;
&#xD;
          -  Patients with a primary diagnosis of bronchial asthma.&#xD;
&#xD;
          -  Patients with a primary diagnosis of COPD associated with at least a 20 pack year&#xD;
             smoking history.&#xD;
&#xD;
          -  Any significant medical condition that is either recently diagnosed or was not stable&#xD;
             during the last 3 months, other than pulmonary exacerbations, and that in the opinion&#xD;
             of the investigator makes participation in the trial against the patients' best&#xD;
             interests.&#xD;
&#xD;
          -  Clinically significant (in the opinion of the investigator) hearing loss that&#xD;
             interferes with patients' daily activities (such as normal conversations) or chronic&#xD;
             tinnitus. Patients with a past history of clinically significant hearing loss in the&#xD;
             opinion of the investigator may be eligible only if their hearing threshold at&#xD;
             screening audiometry is 25dB or lower at frequencies 0.5-4 kHz. The use of a hearing&#xD;
             device is reflective of a clinically significant hearing loss; hence patients using&#xD;
             hearing aids at screening are not eligible.&#xD;
&#xD;
          -  Patients with active pulmonary tuberculosis.&#xD;
&#xD;
          -  Patients currently receiving treatment for nontuberculous mycobacterial (NTM)&#xD;
             pulmonary disease.&#xD;
&#xD;
          -  Patients who are regularly receiving inhaled anti-pseudomonal antibiotic (during the&#xD;
             study inhaled anti-pseudomonal antibiotics are not allowed other than the study drug).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <state>Cedex1</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pordenone</city>
        <state>PN</state>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milan</city>
        <zip>20112</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Scafati</city>
        <zip>84018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunitat Valencia</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baracaldo - Vizcaya</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dundee</city>
        <state>Perthshire</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>ED16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <results_first_submitted>March 17, 2020</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2020</results_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaled tobramycin</keyword>
  <keyword>tobramycin inhalation powder</keyword>
  <keyword>bronchiectasis</keyword>
  <keyword>pulmonary Pseudomonas aeruginosa infection</keyword>
  <keyword>dose-finding study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02712983/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02712983/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 107 subjects were enrolled in the trial from 6 countries (Belgium [2 sites], France [4 sites], Germany [5 sites], Italy [6 sites], Spain [8 sites] and United Kingdom [9 sites]).</recruitment_details>
      <pre_assignment_details>This study planned to recruit approximately 180 subjects to one of the 3 cohorts in a ratio of 1:1:1. The subjects within each cohort were randomized to blinded TIP or placebo with the following randomization scheme: TIP:TIP/Placebo cyclical:Placebo, in a 2:2:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A (3 Capsules o.d.): TIP</title>
          <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="P2">
          <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
          <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="P3">
          <title>Cohort A (3 Capsules o.d.): PBO</title>
          <description>Cohort A (3 capsules o.d.): Inhaled placebo (PBO)</description>
        </group>
        <group group_id="P4">
          <title>Cohort B (5 Capsules o.d.): TIP</title>
          <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="P5">
          <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
          <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="P6">
          <title>Cohort B (5 Capsules o.d.): PBO</title>
          <description>Cohort B (5 capsules o.d.): inhaled placebo (PBO)</description>
        </group>
        <group group_id="P7">
          <title>Cohort C (4 Capsules b.i.d.): TIP</title>
          <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="P8">
          <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
          <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="P9">
          <title>Cohort C (4 Capsules b.i.d.): PBO</title>
          <description>Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Treatment Efficacy Follow-Up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
                <participants group_id="P2" count="1">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
                <participants group_id="P3" count="0">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
                <participants group_id="P4" count="1">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
                <participants group_id="P5" count="2">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
                <participants group_id="P6" count="1">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
                <participants group_id="P7" count="2">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
                <participants group_id="P8" count="3">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
                <participants group_id="P9" count="0">All patients who entered Post-Treatment Efficacy Fup Phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A (3 Capsules o.d.): TIP</title>
          <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="B2">
          <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
          <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="B3">
          <title>Cohort A (3 Capsules o.d.): PBO</title>
          <description>Cohort A (3 capsules o.d.): Inhaled placebo (PBO)</description>
        </group>
        <group group_id="B4">
          <title>Cohort B (5 Capsules o.d.): TIP</title>
          <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="B5">
          <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
          <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="B6">
          <title>Cohort B (5 Capsules o.d.): PBO</title>
          <description>Cohort B (5 capsules o.d.): inhaled placebo (PBO)</description>
        </group>
        <group group_id="B7">
          <title>Cohort C (4 Capsules b.i.d.): TIP</title>
          <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="B8">
          <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
          <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="B9">
          <title>Cohort C (4 Capsules b.i.d.): PBO</title>
          <description>Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="15"/>
            <count group_id="B8" value="15"/>
            <count group_id="B9" value="7"/>
            <count group_id="B10" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="12.66"/>
                    <measurement group_id="B2" value="57.5" spread="11.83"/>
                    <measurement group_id="B3" value="61.3" spread="7.45"/>
                    <measurement group_id="B4" value="64.3" spread="17.86"/>
                    <measurement group_id="B5" value="62.4" spread="16.71"/>
                    <measurement group_id="B6" value="69.1" spread="13.21"/>
                    <measurement group_id="B7" value="66.1" spread="12.23"/>
                    <measurement group_id="B8" value="60.8" spread="12.94"/>
                    <measurement group_id="B9" value="71.3" spread="10.39"/>
                    <measurement group_id="B10" value="63.4" spread="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)</title>
        <description>Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. Change was determined using the formula = (Post-baseline value - baseline value). If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. Only values for all morphotypes presented.</description>
        <time_frame>Baseline (Visit 101/Day 1), Visit 102 (Day 8), Visit 103 (Day 29)</time_frame>
        <population>Full Analysis Set. Only the participants who had microbiological data at specified time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)</title>
          <description>Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. Change was determined using the formula = (Post-baseline value - baseline value). If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. Only values for all morphotypes presented.</description>
          <population>Full Analysis Set. Only the participants who had microbiological data at specified time points were included.</population>
          <units>log10 CFUs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" spread="1.202"/>
                    <measurement group_id="O2" value="7.67" spread="1.507"/>
                    <measurement group_id="O3" value="6.10" spread="2.419"/>
                    <measurement group_id="O4" value="6.98" spread="1.804"/>
                    <measurement group_id="O5" value="6.79" spread="0.908"/>
                    <measurement group_id="O6" value="5.73" spread="1.885"/>
                    <measurement group_id="O7" value="6.57" spread="1.625"/>
                    <measurement group_id="O8" value="6.74" spread="1.892"/>
                    <measurement group_id="O9" value="7.09" spread="2.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.82" spread="1.440"/>
                    <measurement group_id="O2" value="-3.23" spread="2.204"/>
                    <measurement group_id="O3" value="-2.04" spread="2.274"/>
                    <measurement group_id="O4" value="-3.98" spread="1.865"/>
                    <measurement group_id="O5" value="-4.54" spread="1.283"/>
                    <measurement group_id="O6" value="-3.47" spread="1.583"/>
                    <measurement group_id="O7" value="-3.30" spread="1.937"/>
                    <measurement group_id="O8" value="-3.58" spread="1.878"/>
                    <measurement group_id="O9" value="-0.72" spread="1.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.61" spread="2.600"/>
                    <measurement group_id="O2" value="-2.80" spread="2.823"/>
                    <measurement group_id="O3" value="-1.56" spread="2.885"/>
                    <measurement group_id="O4" value="-3.57" spread="2.218"/>
                    <measurement group_id="O5" value="-4.36" spread="1.101"/>
                    <measurement group_id="O6" value="-2.58" spread="2.871"/>
                    <measurement group_id="O7" value="-2.98" spread="2.474"/>
                    <measurement group_id="O8" value="-2.96" spread="2.618"/>
                    <measurement group_id="O9" value="0.05" spread="1.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 8 Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.62</ci_lower_limit>
            <ci_upper_limit>-1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 8 Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.30</ci_lower_limit>
            <ci_upper_limit>-0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 8 Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.20</ci_lower_limit>
            <ci_upper_limit>-0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 8 Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.38</ci_lower_limit>
            <ci_upper_limit>-2.15</ci_upper_limit>
            <other_analysis_desc>LS Mean Diff (SE) vs pooled placebo</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 8 Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-4.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.06</ci_lower_limit>
            <ci_upper_limit>-2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 8 Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.57</ci_lower_limit>
            <ci_upper_limit>-2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 8: Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.66</ci_lower_limit>
            <ci_upper_limit>-1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 8: Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.79</ci_lower_limit>
            <ci_upper_limit>-2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 29 Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.28</ci_lower_limit>
            <ci_upper_limit>-1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 29 Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.03</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 29 Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.04</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 29 Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.16</ci_lower_limit>
            <ci_upper_limit>-1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 29 Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.13</ci_lower_limit>
            <ci_upper_limit>-3.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 29 Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.68</ci_lower_limit>
            <ci_upper_limit>-1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 29: Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.43</ci_lower_limit>
            <ci_upper_limit>-2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 29: Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.19</ci_lower_limit>
            <ci_upper_limit>-1.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Post-baseline Visit in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)</title>
        <description>Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. Change was determined using the formula = (Post-baseline value - baseline value). If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. Only values for all morphotypes are presented.</description>
        <time_frame>Baseline (Visit 101/Day 1), Visit 104 (Day 57), Visit 105 (Day 85), Visit 106 (Day 113), End of Treatment (EOT), Visit 201 (Day 141), Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set. Only the participants who had microbiological data at specified time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Post-baseline Visit in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)</title>
          <description>Microbiological data was collected to understand the direct impact of the drug on the pathogens. Sputum samples were cultured for the presence of three Pseudomonas aeruginosa (P. aeruginosa) biotypes measured were mucoid, dry and small colony variant. Change was determined using the formula = (Post-baseline value - baseline value). If no P. aeruginosa was isolated for a visit, log10 colony forming units (CFU) was imputed with log10 (19) for all biotypes. Only values for all morphotypes are presented.</description>
          <population>Full Analysis Set. Only the participants who had microbiological data at specified time points were included.</population>
          <units>log10 CFUs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" spread="1.202"/>
                    <measurement group_id="O2" value="7.67" spread="1.507"/>
                    <measurement group_id="O3" value="6.10" spread="2.419"/>
                    <measurement group_id="O4" value="6.98" spread="1.804"/>
                    <measurement group_id="O5" value="6.79" spread="0.908"/>
                    <measurement group_id="O6" value="5.73" spread="1.885"/>
                    <measurement group_id="O7" value="6.57" spread="1.625"/>
                    <measurement group_id="O8" value="6.74" spread="1.892"/>
                    <measurement group_id="O9" value="7.09" spread="2.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="3.066"/>
                    <measurement group_id="O2" value="-0.72" spread="2.677"/>
                    <measurement group_id="O3" value="-0.90" spread="1.894"/>
                    <measurement group_id="O4" value="-1.62" spread="2.804"/>
                    <measurement group_id="O5" value="-3.53" spread="2.220"/>
                    <measurement group_id="O6" value="-0.49" spread="2.305"/>
                    <measurement group_id="O7" value="-2.25" spread="2.646"/>
                    <measurement group_id="O8" value="-0.96" spread="2.576"/>
                    <measurement group_id="O9" value="0.20" spread="1.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="26"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="2.446"/>
                    <measurement group_id="O2" value="-2.94" spread="2.492"/>
                    <measurement group_id="O3" value="-2.81" spread="3.653"/>
                    <measurement group_id="O4" value="-3.88" spread="2.470"/>
                    <measurement group_id="O5" value="-3.08" spread="1.624"/>
                    <measurement group_id="O6" value="-2.00" spread="2.951"/>
                    <measurement group_id="O7" value="-2.76" spread="2.446"/>
                    <measurement group_id="O8" value="-3.01" spread="2.641"/>
                    <measurement group_id="O9" value="-0.36" spread="2.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="19"/>
                    <count group_id="O8" value="25"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.94" spread="1.977"/>
                    <measurement group_id="O2" value="-1.03" spread="2.002"/>
                    <measurement group_id="O3" value="-1.82" spread="2.331"/>
                    <measurement group_id="O4" value="-1.99" spread="3.020"/>
                    <measurement group_id="O5" value="-3.17" spread="2.378"/>
                    <measurement group_id="O6" value="-1.54" spread="3.534"/>
                    <measurement group_id="O7" value="-2.79" spread="2.141"/>
                    <measurement group_id="O8" value="-1.50" spread="2.707"/>
                    <measurement group_id="O9" value="-0.20" spread="1.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="36"/>
                    <count group_id="O9" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" spread="1.896"/>
                    <measurement group_id="O2" value="-1.08" spread="1.907"/>
                    <measurement group_id="O3" value="-0.84" spread="1.766"/>
                    <measurement group_id="O4" value="-1.86" spread="2.607"/>
                    <measurement group_id="O5" value="-2.60" spread="2.531"/>
                    <measurement group_id="O6" value="-1.29" spread="3.300"/>
                    <measurement group_id="O7" value="-2.01" spread="2.192"/>
                    <measurement group_id="O8" value="-1.42" spread="2.650"/>
                    <measurement group_id="O9" value="-0.34" spread="1.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="26"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="2.113"/>
                    <measurement group_id="O2" value="-0.82" spread="2.117"/>
                    <measurement group_id="O3" value="0.10" spread="1.551"/>
                    <measurement group_id="O4" value="-2.17" spread="2.863"/>
                    <measurement group_id="O5" value="-0.92" spread="2.385"/>
                    <measurement group_id="O6" value="-0.87" spread="3.640"/>
                    <measurement group_id="O7" value="-0.68" spread="2.067"/>
                    <measurement group_id="O8" value="-1.34" spread="2.793"/>
                    <measurement group_id="O9" value="-0.06" spread="2.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="25"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="2.324"/>
                    <measurement group_id="O2" value="-1.19" spread="1.885"/>
                    <measurement group_id="O3" value="0.46" spread="1.651"/>
                    <measurement group_id="O4" value="-1.27" spread="2.684"/>
                    <measurement group_id="O5" value="0.62" spread="1.038"/>
                    <measurement group_id="O6" value="1.33" spread="4.219"/>
                    <measurement group_id="O7" value="0.03" spread="1.882"/>
                    <measurement group_id="O8" value="-0.51" spread="3.036"/>
                    <measurement group_id="O9" value="0.62" spread="2.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 57 Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.82</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 57 Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.21</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 57 Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.87</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 57 Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.34</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 57 Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.50</ci_lower_limit>
            <ci_upper_limit>-2.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 57 Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.26</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 57: Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.98</ci_lower_limit>
            <ci_upper_limit>-1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 57: Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.50</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.00</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.81</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.96</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.44</ci_lower_limit>
            <ci_upper_limit>-1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.90</ci_lower_limit>
            <ci_upper_limit>-1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85 Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.66</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.11</ci_lower_limit>
            <ci_upper_limit>-1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 85: Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.12</ci_lower_limit>
            <ci_upper_limit>-1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113 Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.55</ci_lower_limit>
            <ci_upper_limit>-1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113 Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113 Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.93</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113 Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.62</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113 Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.94</ci_lower_limit>
            <ci_upper_limit>-1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113 Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.37</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.24</ci_lower_limit>
            <ci_upper_limit>-1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 113: Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.73</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>EoT Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>-0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>EoT Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>EoT Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.81</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>EoT Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.14</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>EoT Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.89</ci_lower_limit>
            <ci_upper_limit>-0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>EoT Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.12</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>EoT: Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.08</ci_lower_limit>
            <ci_upper_limit>-0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>EoT: Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 141 Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.63</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 141 Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 141 Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.03</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 141 Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.68</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 141 Cohort C (4 capsules b.i.d.): TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 141 Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.36</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 141: Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 141: Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.45</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 169 Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.24</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 169 Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.05</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 169 Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.73</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 169 Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.22</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 169 Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 169 Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 169: Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.24</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Day 169: Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.61</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Onset of Pulmonary Exacerbation by Exacerbation Category</title>
        <description>The time to first onset of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization. Participants were censored at the time of completion of study or early discontinuation if they did not have a pulmonary exacerbation during the study period.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Onset of Pulmonary Exacerbation by Exacerbation Category</title>
          <description>The time to first onset of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization. Participants were censored at the time of completion of study or early discontinuation if they did not have a pulmonary exacerbation during the study period.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="39.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="48.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="15.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="85.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="127.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="24.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="127.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="85.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="173.00" lower_limit="77.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="48.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="22.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="85.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="84.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="173.00" lower_limit="106.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parenteral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="110.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="60.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="154.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="33.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>3.77</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>3.62</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>3.93</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>10.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>104.19</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>52.29</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>37.06</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>25.94</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>11.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>117.34</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>37.32</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Pulmonary Exacerbation by Exacerbation Category</title>
        <description>The duration of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Pulmonary Exacerbation by Exacerbation Category</title>
          <description>The duration of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="6.22"/>
                    <measurement group_id="O2" value="18.0" spread="8.26"/>
                    <measurement group_id="O3" value="20.2" spread="6.37"/>
                    <measurement group_id="O4" value="10.3" spread="5.12"/>
                    <measurement group_id="O5" value="25.5" spread="27.09"/>
                    <measurement group_id="O6" value="14.8" spread="6.73"/>
                    <measurement group_id="O7" value="19.0" spread="12.64"/>
                    <measurement group_id="O8" value="15.2" spread="7.39"/>
                    <measurement group_id="O9" value="14.5" spread="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="12.02"/>
                    <measurement group_id="O2" value="15.4" spread="4.24"/>
                    <measurement group_id="O3" value="19.3" spread="3.20"/>
                    <measurement group_id="O4" value="8.3" spread="4.16"/>
                    <measurement group_id="O5" value="14.0" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="16.3" spread="5.51"/>
                    <measurement group_id="O7" value="18.6" spread="5.77"/>
                    <measurement group_id="O8" value="14.0" spread="5.24"/>
                    <measurement group_id="O9" value="15.6" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parenteral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="5.52"/>
                    <measurement group_id="O3" value="22.0" spread="12.73"/>
                    <measurement group_id="O4" value="16.0" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="66.0" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="16.8" spread="4.86"/>
                    <measurement group_id="O7" value="23.1" spread="18.73"/>
                    <measurement group_id="O8" value="16.6" spread="4.22"/>
                    <measurement group_id="O9" value="10.0" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>9.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.15</ci_lower_limit>
            <ci_upper_limit>46.81</ci_upper_limit>
            <estimate_desc>ANCOVA model includes treatment as a fixed-effect factor and number of pulmonary exacerbations in the 12 months prior to screening as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>19.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>20.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.63</ci_lower_limit>
            <ci_upper_limit>62.14</ci_upper_limit>
            <estimate_desc>ANCOVA model includes treatment as a fixed-effect factor and number of pulmonary exacerbations in the 12 months prior to screening as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>8.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.32</ci_lower_limit>
            <ci_upper_limit>47.26</ci_upper_limit>
            <estimate_desc>ANCOVA model includes treatment as a fixed-effect factor and number of pulmonary exacerbations in the 12 months prior to screening as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>12.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.49</ci_lower_limit>
            <ci_upper_limit>51.89</ci_upper_limit>
            <estimate_desc>ANCOVA model includes treatment as a fixed-effect factor and number of pulmonary exacerbations in the 12 months prior to screening as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>46.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>21.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.37</ci_lower_limit>
            <ci_upper_limit>89.61</ci_upper_limit>
            <estimate_desc>ANCOVA model includes treatment as a fixed-effect factor and number of pulmonary exacerbations in the 12 months prior to screening as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.21</ci_lower_limit>
            <ci_upper_limit>40.64</ci_upper_limit>
            <estimate_desc>ANCOVA model includes treatment as a fixed-effect factor and number of pulmonary exacerbations in the 12 months prior to screening as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>21.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.03</ci_lower_limit>
            <ci_upper_limit>50.89</ci_upper_limit>
            <estimate_desc>ANCOVA model includes treatment as a fixed-effect factor and number of pulmonary exacerbations in the 12 months prior to screening as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Diff (SE) vs pooled placebo</param_type>
            <param_value>11.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.52</ci_lower_limit>
            <ci_upper_limit>41.29</ci_upper_limit>
            <estimate_desc>ANCOVA model includes treatment as a fixed-effect factor and number of pulmonary exacerbations in the 12 months prior to screening as a covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exposure Adjusted Rate of Pulmonary Exacerbations (PE) Over the Entire Study Period</title>
        <description>The exposure adjusted rate of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization. The Exposure adjusted rate = (Number of pulmonary exacerbations reported during the study period) / (sum of study duration in days for all participants/ 365.25). Only descriptive analysis performed.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Exposure Adjusted Rate of Pulmonary Exacerbations (PE) Over the Entire Study Period</title>
          <description>The exposure adjusted rate of pulmonary exacerbation compared to placebo was analyzed. Participants with pulmonary exacerbation were categorized as: a) Overall, b) Category 1 (Oral): treated with oral antibiotics only and c) Category 2 (Parenteral): treated with parenteral Antibiotics and/or requiring hospitalization. The Exposure adjusted rate = (Number of pulmonary exacerbations reported during the study period) / (sum of study duration in days for all participants/ 365.25). Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>pulmonary exacerbation per study years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="0.92" upper_limit="3.17"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.70" upper_limit="2.78"/>
                    <measurement group_id="O3" value="1.29" lower_limit="0.58" upper_limit="2.87"/>
                    <measurement group_id="O4" value="1.20" lower_limit="0.57" upper_limit="2.51"/>
                    <measurement group_id="O5" value="0.66" lower_limit="0.25" upper_limit="1.76"/>
                    <measurement group_id="O6" value="1.46" lower_limit="0.73" upper_limit="2.93"/>
                    <measurement group_id="O7" value="1.21" lower_limit="0.78" upper_limit="1.87"/>
                    <measurement group_id="O8" value="1.35" lower_limit="0.90" upper_limit="2.03"/>
                    <measurement group_id="O9" value="1.41" lower_limit="0.82" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="0.09" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.22" lower_limit="0.58" upper_limit="2.56"/>
                    <measurement group_id="O3" value="0.86" lower_limit="0.32" upper_limit="2.29"/>
                    <measurement group_id="O4" value="0.85" lower_limit="0.36" upper_limit="2.05"/>
                    <measurement group_id="O5" value="0.16" lower_limit="0.02" upper_limit="1.17"/>
                    <measurement group_id="O6" value="0.55" lower_limit="0.18" upper_limit="1.70"/>
                    <measurement group_id="O7" value="0.42" lower_limit="0.20" upper_limit="0.89"/>
                    <measurement group_id="O8" value="0.88" lower_limit="0.53" upper_limit="1.46"/>
                    <measurement group_id="O9" value="1.19" lower_limit="0.66" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parenteral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.36" upper_limit="2.05"/>
                    <measurement group_id="O3" value="0.43" lower_limit="0.11" upper_limit="1.72"/>
                    <measurement group_id="O4" value="0.34" lower_limit="0.09" upper_limit="1.37"/>
                    <measurement group_id="O5" value="0.16" lower_limit="0.02" upper_limit="1.17"/>
                    <measurement group_id="O6" value="0.73" lower_limit="0.27" upper_limit="1.95"/>
                    <measurement group_id="O7" value="0.48" lower_limit="0.24" upper_limit="0.96"/>
                    <measurement group_id="O8" value="0.35" lower_limit="0.16" upper_limit="0.78"/>
                    <measurement group_id="O9" value="0.11" lower_limit="0.02" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Pulmonary Exacerbation by Exacerbation Category</title>
        <description>Pulmonary exacerbations are defined as events requiring antibiotic therapy AND for which at least 3 of the following 6 symptoms, signs, or findings were present outside of normal variation: 1. Increased sputum volume, or change in viscosity/consistency or purulence for more than 24 hours; 2. Increased shortness of breath at rest or on exercise for more than 24 hours; 3. Increased cough for more than 24 hours; 4. Fever of ≥38° Celsius within the last 24 hours; 5. Increased malaise/fatigue/lethargy for more than 24 hours; 6. A reduction in forced expiratory volume in the first second of expiration (FEV1) or forced vital capacity (FVC) of least 10% from screening.&#xD;
Participants were categorized as: a) Overall, b) Category 1: treated with oral antibiotics only and c) Category 2: treated with parenteral Antibiotics and/or requiring hospitalization.&#xD;
Only descriptive analysis performed.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Pulmonary Exacerbation by Exacerbation Category</title>
          <description>Pulmonary exacerbations are defined as events requiring antibiotic therapy AND for which at least 3 of the following 6 symptoms, signs, or findings were present outside of normal variation: 1. Increased sputum volume, or change in viscosity/consistency or purulence for more than 24 hours; 2. Increased shortness of breath at rest or on exercise for more than 24 hours; 3. Increased cough for more than 24 hours; 4. Fever of ≥38° Celsius within the last 24 hours; 5. Increased malaise/fatigue/lethargy for more than 24 hours; 6. A reduction in forced expiratory volume in the first second of expiration (FEV1) or forced vital capacity (FVC) of least 10% from screening.&#xD;
Participants were categorized as: a) Overall, b) Category 1: treated with oral antibiotics only and c) Category 2: treated with parenteral Antibiotics and/or requiring hospitalization.&#xD;
Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <title>No of participants with no events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="27"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 1 event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 2 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 3 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral</title>
              <category_list>
                <category>
                  <title>No of participants with no events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="31"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 1 event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 2 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 3 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parenteral</title>
              <category_list>
                <category>
                  <title>No of participants with no events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 1 event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 2 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 3 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Permanently Discontinued Study Drug Due to Pulmonary Exacerbation</title>
        <description>The percentage of participants who permanently discontinued study drug due to pulmonary exacerbation compared to placebo was analyzed.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Permanently Discontinued Study Drug Due to Pulmonary Exacerbation</title>
          <description>The percentage of participants who permanently discontinued study drug due to pulmonary exacerbation compared to placebo was analyzed.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="41"/>
                    <measurement group_id="O8" value="40"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Permanent Study Drug Discontinuation Due to Pulmonary Exacerbation</title>
        <description>The time to permanent study drug discontinuation due to Pulmonary exacerbation. Participants were censored at the time of last contact if they did not permanently discontinue study drug due to pulmonary exacerbation requiring during the study period. Only descriptive analysis performed.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Permanent Study Drug Discontinuation Due to Pulmonary Exacerbation</title>
          <description>The time to permanent study drug discontinuation due to Pulmonary exacerbation. Participants were censored at the time of last contact if they did not permanently discontinue study drug due to pulmonary exacerbation requiring during the study period. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="94.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="84.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use (Overall, Oral, and Parenteral) of Anti-pseudomonal Antibiotics Usage</title>
        <description>The time to first use of anti-pseudomonal antibiotics administered compared to placebo was analyzed. Participants were censored at the time of last contact if they did not have anti-pseudomonal antibiotics over the entire study period.</description>
        <time_frame>From Baseline (Visit 101/Day 1) up to approximately Day 173</time_frame>
        <population>Full Analysis Set. Only the participants who required antipseudomonal antibiotics were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use (Overall, Oral, and Parenteral) of Anti-pseudomonal Antibiotics Usage</title>
          <description>The time to first use of anti-pseudomonal antibiotics administered compared to placebo was analyzed. Participants were censored at the time of last contact if they did not have anti-pseudomonal antibiotics over the entire study period.</description>
          <population>Full Analysis Set. Only the participants who required antipseudomonal antibiotics were included.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.00" lower_limit="29.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="50.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="116.00" lower_limit="17.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="161.00" lower_limit="58.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="127.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="11.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="110.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="84.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="141.00" lower_limit="57.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="43.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="50.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="17.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="85.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="11.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="85.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="173.00" lower_limit="106.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parenteral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="105.0" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="63.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="95.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="37.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Overall Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort A: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>3.60</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>3.73</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Oral Pooled TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort A: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>16.52</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort B: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>8.16</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort B: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>10.05</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort C: TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>4.87</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Parenteral Cohort C: TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>12.49</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Paremteral Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>5.68</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Anti-pseudomonal Antibiotics</title>
        <description>The percentage of participants requiring anti-pseudomonal antibiotics compared to placebo was analyzed. Only descriptive analysis performed.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Anti-pseudomonal Antibiotics</title>
          <description>The percentage of participants requiring anti-pseudomonal antibiotics compared to placebo was analyzed. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <title>Any anti-pseudomonal antibiotic use?=Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any anti-pseudomonal antibiotic use?=No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="24"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral</title>
              <category_list>
                <category>
                  <title>Any anti-pseudomonal antibiotic use?=Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any anti-pseudomonal antibiotic use?=No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parenteral</title>
              <category_list>
                <category>
                  <title>Any anti-pseudomonal antibiotic use?=Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any anti-pseudomonal antibiotic use?=No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="34"/>
                    <measurement group_id="O9" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Anti-pseudomonal Antibiotics Usage</title>
        <description>The total number of days of new anti-pseudomonal antibiotic use compared to placebo was analyzed. Only descriptive analysis</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Anti-pseudomonal Antibiotics Usage</title>
          <description>The total number of days of new anti-pseudomonal antibiotic use compared to placebo was analyzed. Only descriptive analysis</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="18"/>
                    <count group_id="O9" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="10.39"/>
                    <measurement group_id="O2" value="20.0" spread="12.03"/>
                    <measurement group_id="O3" value="19.2" spread="14.84"/>
                    <measurement group_id="O4" value="25.7" spread="13.21"/>
                    <measurement group_id="O5" value="15.3" spread="10.07"/>
                    <measurement group_id="O6" value="15.7" spread="10.90"/>
                    <measurement group_id="O7" value="18.1" spread="11.43"/>
                    <measurement group_id="O8" value="20.6" spread="12.24"/>
                    <measurement group_id="O9" value="14.6" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="7.79"/>
                    <measurement group_id="O2" value="19.8" spread="12.34"/>
                    <measurement group_id="O3" value="15.0" spread="7.42"/>
                    <measurement group_id="O4" value="14.0" spread="10.92"/>
                    <measurement group_id="O5" value="20.0" spread="8.49"/>
                    <measurement group_id="O6" value="10.8" spread="6.24"/>
                    <measurement group_id="O7" value="15.5" spread="7.29"/>
                    <measurement group_id="O8" value="14.3" spread="9.79"/>
                    <measurement group_id="O9" value="13.7" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parenteral</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="10.02"/>
                    <measurement group_id="O3" value="20.0" spread="14.14"/>
                    <measurement group_id="O4" value="23.8" spread="15.20"/>
                    <measurement group_id="O5" value="6.0" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="11.3" spread="2.75"/>
                    <measurement group_id="O7" value="15.1" spread="10.23"/>
                    <measurement group_id="O8" value="17.5" spread="12.12"/>
                    <measurement group_id="O9" value="12.7" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Hospitalization Due to Serious Respiratory-related Adverse Events</title>
        <description>The percentage of participants requiring hospitalization due to serious respiratory-related adverse events (other than those regularly scheduled hospitalization that were planned prior to study start) was analyzed to define severity of pulmonary exacerbations compared to placebo. Only descriptive analysis performed.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Hospitalization Due to Serious Respiratory-related Adverse Events</title>
          <description>The percentage of participants requiring hospitalization due to serious respiratory-related adverse events (other than those regularly scheduled hospitalization that were planned prior to study start) was analyzed to define severity of pulmonary exacerbations compared to placebo. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No of participants with 0 event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 1 event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with 2 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No. of participants with &gt; 2 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization Due to Serious Respiratory-related Adverse Events</title>
        <description>The duration of hospitalization due to serious respiratory-related adverse events (other than those regularly scheduled hospitalization that were planned prior to study start) was analyzed to define severity of pulmonary exacerbations compared to placebo. Only descriptive analysis performed.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set. Only the participants with at least one hospitalization are included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization Due to Serious Respiratory-related Adverse Events</title>
          <description>The duration of hospitalization due to serious respiratory-related adverse events (other than those regularly scheduled hospitalization that were planned prior to study start) was analyzed to define severity of pulmonary exacerbations compared to placebo. Only descriptive analysis performed.</description>
          <population>Full Analysis Set. Only the participants with at least one hospitalization are included in the analysis</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="5.19"/>
                    <measurement group_id="O3" value="22.0" spread="12.73"/>
                    <measurement group_id="O4" value="12.2" spread="6.06"/>
                    <measurement group_id="O5" value="11.0" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="19.0" spread="5.23"/>
                    <measurement group_id="O7" value="16.2" spread="7.05"/>
                    <measurement group_id="O8" value="15.2" spread="6.44"/>
                    <measurement group_id="O9" value="10.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalization Due to Serious Respiratory-related Adverse Events</title>
        <description>The number of hospitalization due to serious respiratory-related AEs was analyzed to define severity of pulmonary exacerbations compared to placebo. Respiratory related adverse events were identified using the AEs captured under system organ class 'Respiratory, thoracic and mediastinal disorders' and 'Infections and infestations'.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalization Due to Serious Respiratory-related Adverse Events</title>
          <description>The number of hospitalization due to serious respiratory-related AEs was analyzed to define severity of pulmonary exacerbations compared to placebo. Respiratory related adverse events were identified using the AEs captured under system organ class 'Respiratory, thoracic and mediastinal disorders' and 'Infections and infestations'.</description>
          <population>Full Analysis Set</population>
          <units>Hospitalization</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort A (3 capsules o.d.): TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio, log</param_type>
            <param_value>5.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>38.18</ci_upper_limit>
            <estimate_desc>Generalized linear model assuming the negative binomial distribution including treatment and baseline macrolide use as class-effect factors. The log exposure to study in years is included as an offset variable in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort B (5 capsules o.d.): TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio, log</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>19.16</ci_upper_limit>
            <estimate_desc>Generalized linear model assuming the negative binomial distribution including treatment and baseline macrolide use as class-effect factors. The log exposure to study in years is included as an offset variable in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort B (5 capsules o.d.): TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio, log</param_type>
            <param_value>3.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>21.80</ci_upper_limit>
            <estimate_desc>Generalized linear model assuming the negative binomial distribution including treatment and baseline macrolide use as class-effect factors. The log exposure to study in years is included as an offset variable in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort C (4 capsules b.i.d.): TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio, log</param_type>
            <param_value>1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>17.42</ci_upper_limit>
            <estimate_desc>Generalized linear model assuming the negative binomial distribution including treatment and baseline macrolide use as class-effect factors. The log exposure to study in years is included as an offset variable in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort C (4 capsules b.i.d.): TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio, log</param_type>
            <param_value>3.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>25.03</ci_upper_limit>
            <estimate_desc>Generalized linear model assuming the negative binomial distribution including treatment and baseline macrolide use as class-effect factors. The log exposure to study in years is included as an offset variable in the model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio, log</param_type>
            <param_value>2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>16.07</ci_upper_limit>
            <estimate_desc>Generalized linear model assuming the negative binomial distribution including treatment and baseline macrolide use as class-effect factors. The log exposure to study in years is included as an offset variable in the model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Hospitalization Due to Serious Respiratory-related Adverse Events</title>
        <description>Time to first hospitalization due to serious respiratory-related AEs was analyzed to define severity of pulmonary exacerbations compared to placebo. Participants were censored at the time of last contact if they did not have a hospitalization due to serious respiratory-related adverse events over the entire study period.</description>
        <time_frame>Baseline (Visit 101/Day 1) to Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Hospitalization Due to Serious Respiratory-related Adverse Events</title>
          <description>Time to first hospitalization due to serious respiratory-related AEs was analyzed to define severity of pulmonary exacerbations compared to placebo. Participants were censored at the time of last contact if they did not have a hospitalization due to serious respiratory-related adverse events over the entire study period.</description>
          <population>Full Analysis Set</population>
          <units>Day</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="93.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="60.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="65.00" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort A (3 capsules o.d.): TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>26.42</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort B (5 capsules o.d.): TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>14.47</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort B (5 capsules o.d.): TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>11.60</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort C (4 capsules b.i.d.): TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>7.49</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort C (4 capsules b.i.d.): TIP/PBO, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>23.29</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled TIP, Pooled PBO</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>9.45</ci_upper_limit>
            <estimate_desc>Based on Cox proportional hazards model with treatment as fixed effect and number of pulmonary exacerbations in the 12 months prior to screening as a covariate, stratified by baseline macrolide use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Tobramycin Concentration</title>
        <description>The serum pharmacokinetic (PK) properties of tobramycin were assessed by evaluating tobramycin concentrations in serum collected from the non-cystic fibrosis bronchiectasis population post administration of o.d. or b.i.d. doses of TIP. Serum specimens for PK tobramycin concentration were assessed at Visit 101 (Day 1/start of treatment) 0 to 1 and 1 to 2 hours post-dose and Visit 102 (Day 8) 0 to 1 and 1 to 2 hours post-dose. Prior to protocol amendment #2, PK samples were assessed on Visits 103 (Day 29) rather than Visit 102. Only descriptive analysis performed.</description>
        <time_frame>Baseline (Visit 101/Day 1), Visit 102 (Day 8) and Visits 103 (Day 29): 0-1 hours and 1-2 hours post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set. Prior to protocol amendment #2, PK samples were assessed on Visit 103 (Day 29) rather than Visit 102 (Day 8).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Tobramycin Concentration</title>
          <description>The serum pharmacokinetic (PK) properties of tobramycin were assessed by evaluating tobramycin concentrations in serum collected from the non-cystic fibrosis bronchiectasis population post administration of o.d. or b.i.d. doses of TIP. Serum specimens for PK tobramycin concentration were assessed at Visit 101 (Day 1/start of treatment) 0 to 1 and 1 to 2 hours post-dose and Visit 102 (Day 8) 0 to 1 and 1 to 2 hours post-dose. Prior to protocol amendment #2, PK samples were assessed on Visits 103 (Day 29) rather than Visit 102. Only descriptive analysis performed.</description>
          <population>Pharmacokinetic Analysis Set. Prior to protocol amendment #2, PK samples were assessed on Visit 103 (Day 29) rather than Visit 102 (Day 8).</population>
          <units>microgram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 101 (Day 1)/0-1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.256" spread="0.144"/>
                    <measurement group_id="O2" value="0.479" spread="0.47"/>
                    <measurement group_id="O3" value="0.4" spread="0.259"/>
                    <measurement group_id="O4" value="0.441" spread="0.273"/>
                    <measurement group_id="O5" value="0.59" spread="0.37"/>
                    <measurement group_id="O6" value="0.321" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 101 (Day 1)/1-2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.481" spread="0.287"/>
                    <measurement group_id="O2" value="0.571" spread="0.349"/>
                    <measurement group_id="O3" value="0.517" spread="0.392"/>
                    <measurement group_id="O4" value="0.624" spread="0.322"/>
                    <measurement group_id="O5" value="0.64" spread="0.338"/>
                    <measurement group_id="O6" value="0.476" spread="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 102 (Day 8)/0-1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="1.81" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="0.258" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="1.4" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="0.489" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 102 (Day 8)/1-2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.18" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="1.67" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="0.588" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O5" value="1.48" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="0.447" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 103 (Day 29)/0-1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.607" spread="0.455"/>
                    <measurement group_id="O2" value="0.0718" spread="0.0498"/>
                    <measurement group_id="O3" value="1.23" spread="1.08"/>
                    <measurement group_id="O4" value="0.103" spread="0.0983"/>
                    <measurement group_id="O5" value="1.05" spread="0.603"/>
                    <measurement group_id="O6" value="0.339" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 103 (Day 29)/1-2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.768" spread="0.477"/>
                    <measurement group_id="O2" value="0.0818" spread="0.0972"/>
                    <measurement group_id="O3" value="1.37" spread="0.647"/>
                    <measurement group_id="O4" value="0.104" spread="0.096"/>
                    <measurement group_id="O5" value="1.05" spread="0.622"/>
                    <measurement group_id="O6" value="0.307" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Tobramycin Concentration</title>
        <description>The sputum pharmacokinetic (PK) properties of tobramycin were assessed by evaluating tobramycin concentrations in sputum collected from the non-cystic fibrosis bronchiectasis population post administration of o.d. or b.i.d. doses of TIP. Only descriptive analysis performed.</description>
        <time_frame>Baseline (Visit 101/Day 1): 0-1 hours and 1-2 hours post-dose; Visit 102 (Day 8):0-2 hours and 5-6 hours post-dose; Visits 103 (Day 29): 5 to 6 hours post-dose, Visit 104 (Day 57) and Visit 105 (Day 85): 3-4 hours post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set. Prior to protocol amendment #2, Sputum specimens for PK assessments were collected at Visit 103 (Day 29) 5 to 6 hours rather than Visit 102 (Day 8) 0 to 2 and 5 to 6 hours and on Visit 105 (Day 85) 3 to 4 hours rather than Visit 104 (Day 57) 3 to 4 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Tobramycin Concentration</title>
          <description>The sputum pharmacokinetic (PK) properties of tobramycin were assessed by evaluating tobramycin concentrations in sputum collected from the non-cystic fibrosis bronchiectasis population post administration of o.d. or b.i.d. doses of TIP. Only descriptive analysis performed.</description>
          <population>Pharmacokinetic Analysis Set. Prior to protocol amendment #2, Sputum specimens for PK assessments were collected at Visit 103 (Day 29) 5 to 6 hours rather than Visit 102 (Day 8) 0 to 2 and 5 to 6 hours and on Visit 105 (Day 85) 3 to 4 hours rather than Visit 104 (Day 57) 3 to 4 hours.</population>
          <units>microgram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 101 (Day 1)/0-1 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1750" spread="2160"/>
                    <measurement group_id="O2" value="637" spread="608"/>
                    <measurement group_id="O3" value="2640" spread="2680"/>
                    <measurement group_id="O4" value="2020" spread="2360"/>
                    <measurement group_id="O5" value="2820" spread="2250"/>
                    <measurement group_id="O6" value="2060" spread="1840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 101 (Day 1)/1-2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100" spread="2480"/>
                    <measurement group_id="O2" value="204" spread="445"/>
                    <measurement group_id="O3" value="1650" spread="2340"/>
                    <measurement group_id="O4" value="1100" spread="2310"/>
                    <measurement group_id="O5" value="631" spread="441"/>
                    <measurement group_id="O6" value="610" spread="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 102 (Day 8)/0-2 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1440" spread="1470"/>
                    <measurement group_id="O2" value="2390" spread="2730"/>
                    <measurement group_id="O3" value="2460" spread="761"/>
                    <measurement group_id="O4" value="4290" spread="3730"/>
                    <measurement group_id="O5" value="1980" spread="2060"/>
                    <measurement group_id="O6" value="2290" spread="1560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 102 (Day 8)/5-6 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="32.4" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="4460" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="1200" spread="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 103 (Day 29)/5-6 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389" spread="554"/>
                    <measurement group_id="O2" value="136" spread="258"/>
                    <measurement group_id="O3" value="915" spread="1450"/>
                    <measurement group_id="O4" value="16.3" spread="28.6"/>
                    <measurement group_id="O5" value="620" spread="513"/>
                    <measurement group_id="O6" value="134" spread="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 104 (Day 57)/3-4 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" spread="138"/>
                    <measurement group_id="O2" value="0" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="96.4" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="4540" spread="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 105 (Day 85)/3-4 hr post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="791" spread="883"/>
                    <measurement group_id="O2" value="45.7" spread="75.8"/>
                    <measurement group_id="O3" value="101" spread="100"/>
                    <measurement group_id="O4" value="61" spread="108"/>
                    <measurement group_id="O5" value="2810" spread="2200"/>
                    <measurement group_id="O6" value="121" spread="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Physical Functioning</title>
        <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
        <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Physical Functioning</title>
          <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="42"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.33" spread="38.33"/>
                    <measurement group_id="O2" value="60.5" spread="28.60"/>
                    <measurement group_id="O3" value="45.8" spread="19.98"/>
                    <measurement group_id="O4" value="50.5" spread="33.04"/>
                    <measurement group_id="O5" value="46.2" spread="30.29"/>
                    <measurement group_id="O6" value="53.8" spread="26.72"/>
                    <measurement group_id="O7" value="47.6" spread="29.41"/>
                    <measurement group_id="O8" value="54.8" spread="29.10"/>
                    <measurement group_id="O9" value="49.8" spread="27.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="18.83"/>
                    <measurement group_id="O2" value="-2.8" spread="14.35"/>
                    <measurement group_id="O3" value="-6.7" spread="22.02"/>
                    <measurement group_id="O4" value="-2.9" spread="18.06"/>
                    <measurement group_id="O5" value="0.9" spread="11.51"/>
                    <measurement group_id="O6" value="3.1" spread="14.44"/>
                    <measurement group_id="O7" value="0.2" spread="17.83"/>
                    <measurement group_id="O8" value="-0.7" spread="15.62"/>
                    <measurement group_id="O9" value="-7.4" spread="17.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="24.40"/>
                    <measurement group_id="O2" value="-7.2" spread="16.44"/>
                    <measurement group_id="O3" value="-5.3" spread="27.90"/>
                    <measurement group_id="O4" value="-2.6" spread="8.41"/>
                    <measurement group_id="O5" value="-0.4" spread="16.23"/>
                    <measurement group_id="O6" value="-6.2" spread="27.48"/>
                    <measurement group_id="O7" value="-2.3" spread="22.04"/>
                    <measurement group_id="O8" value="-5.3" spread="19.05"/>
                    <measurement group_id="O9" value="-1.1" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="18.66"/>
                    <measurement group_id="O2" value="-6.1" spread="18.53"/>
                    <measurement group_id="O3" value="-19.4" spread="23.00"/>
                    <measurement group_id="O4" value="-6.7" spread="23.39"/>
                    <measurement group_id="O5" value="-5.8" spread="31.36"/>
                    <measurement group_id="O6" value="-9.8" spread="30.43"/>
                    <measurement group_id="O7" value="-10.2" spread="25.44"/>
                    <measurement group_id="O8" value="-7.6" spread="24.47"/>
                    <measurement group_id="O9" value="0.4" spread="20.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="25.27"/>
                    <measurement group_id="O2" value="-3.3" spread="18.09"/>
                    <measurement group_id="O3" value="0.0" spread="22.44"/>
                    <measurement group_id="O4" value="-1.3" spread="16.27"/>
                    <measurement group_id="O5" value="-3.9" spread="26.43"/>
                    <measurement group_id="O6" value="7.3" spread="22.54"/>
                    <measurement group_id="O7" value="0.4" spread="24.43"/>
                    <measurement group_id="O8" value="0.6" spread="19.04"/>
                    <measurement group_id="O9" value="-4.8" spread="16.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Role Functioning</title>
        <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
        <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Role Functioning</title>
          <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="42"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="24.28"/>
                    <measurement group_id="O2" value="67.2" spread="14.26"/>
                    <measurement group_id="O3" value="53.3" spread="21.68"/>
                    <measurement group_id="O4" value="64.3" spread="29.77"/>
                    <measurement group_id="O5" value="57.8" spread="26.86"/>
                    <measurement group_id="O6" value="67.6" spread="24.67"/>
                    <measurement group_id="O7" value="57.8" spread="24.11"/>
                    <measurement group_id="O8" value="66.3" spread="23.46"/>
                    <measurement group_id="O9" value="63.9" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="14.36"/>
                    <measurement group_id="O2" value="-2.2" spread="19.76"/>
                    <measurement group_id="O3" value="2.2" spread="20.17"/>
                    <measurement group_id="O4" value="-1.4" spread="13.88"/>
                    <measurement group_id="O5" value="3.6" spread="17.43"/>
                    <measurement group_id="O6" value="-4.2" spread="20.95"/>
                    <measurement group_id="O7" value="3.8" spread="17.01"/>
                    <measurement group_id="O8" value="-2.7" spread="18.03"/>
                    <measurement group_id="O9" value="-1.4" spread="14.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="19.66"/>
                    <measurement group_id="O2" value="-1.1" spread="18.17"/>
                    <measurement group_id="O3" value="2.0" spread="21.33"/>
                    <measurement group_id="O4" value="-1.0" spread="14.87"/>
                    <measurement group_id="O5" value="-0.9" spread="19.82"/>
                    <measurement group_id="O6" value="-4.5" spread="23.88"/>
                    <measurement group_id="O7" value="0.7" spread="19.65"/>
                    <measurement group_id="O8" value="-2.3" spread="19.06"/>
                    <measurement group_id="O9" value="1.8" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="23.95"/>
                    <measurement group_id="O2" value="-5.0" spread="24.47"/>
                    <measurement group_id="O3" value="-0.4" spread="23.79"/>
                    <measurement group_id="O4" value="-9.0" spread="25.30"/>
                    <measurement group_id="O5" value="0.9" spread="20.30"/>
                    <measurement group_id="O6" value="-4.0" spread="24.27"/>
                    <measurement group_id="O7" value="0.0" spread="22.01"/>
                    <measurement group_id="O8" value="-6.0" spread="24.17"/>
                    <measurement group_id="O9" value="1.0" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="16.96"/>
                    <measurement group_id="O2" value="-7.2" spread="17.17"/>
                    <measurement group_id="O3" value="10.7" spread="13.41"/>
                    <measurement group_id="O4" value="-2.7" spread="21.82"/>
                    <measurement group_id="O5" value="-6.1" spread="15.94"/>
                    <measurement group_id="O6" value="6.7" spread="16.92"/>
                    <measurement group_id="O7" value="4.4" spread="17.13"/>
                    <measurement group_id="O8" value="-1.5" spread="18.99"/>
                    <measurement group_id="O9" value="-4.4" spread="15.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Vitality</title>
        <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
        <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Vitality</title>
          <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="42"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="22.89"/>
                    <measurement group_id="O2" value="47.9" spread="17.21"/>
                    <measurement group_id="O3" value="52.4" spread="21.54"/>
                    <measurement group_id="O4" value="44.4" spread="26.51"/>
                    <measurement group_id="O5" value="47.4" spread="25.36"/>
                    <measurement group_id="O6" value="51.9" spread="18.63"/>
                    <measurement group_id="O7" value="51.9" spread="23.11"/>
                    <measurement group_id="O8" value="48.1" spread="20.92"/>
                    <measurement group_id="O9" value="46.2" spread="25.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="39"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="18.45"/>
                    <measurement group_id="O2" value="1.9" spread="24.54"/>
                    <measurement group_id="O3" value="-6.1" spread="31.18"/>
                    <measurement group_id="O4" value="4.8" spread="17.27"/>
                    <measurement group_id="O5" value="5.2" spread="20.52"/>
                    <measurement group_id="O6" value="2.2" spread="11.27"/>
                    <measurement group_id="O7" value="2.6" spread="23.43"/>
                    <measurement group_id="O8" value="3.0" spread="17.57"/>
                    <measurement group_id="O9" value="-2.9" spread="16.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="37"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="30.95"/>
                    <measurement group_id="O2" value="4.6" spread="15.23"/>
                    <measurement group_id="O3" value="-9.9" spread="28.57"/>
                    <measurement group_id="O4" value="3.4" spread="18.36"/>
                    <measurement group_id="O5" value="-0.7" spread="24.66"/>
                    <measurement group_id="O6" value="-5.6" spread="23.77"/>
                    <measurement group_id="O7" value="-4.2" spread="27.39"/>
                    <measurement group_id="O8" value="80.6" spread="19.74"/>
                    <measurement group_id="O9" value="1.8" spread="19.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="39"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="25.26"/>
                    <measurement group_id="O2" value="2.8" spread="24.22"/>
                    <measurement group_id="O3" value="-12.1" spread="26.04"/>
                    <measurement group_id="O4" value="3.2" spread="28.05"/>
                    <measurement group_id="O5" value="-0.7" spread="29.24"/>
                    <measurement group_id="O6" value="2.2" spread="30.35"/>
                    <measurement group_id="O7" value="-5.6" spread="26.77"/>
                    <measurement group_id="O8" value="2.7" spread="27.19"/>
                    <measurement group_id="O9" value="-1.2" spread="23.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="20.55"/>
                    <measurement group_id="O2" value="3.7" spread="22.89"/>
                    <measurement group_id="O3" value="3.7" spread="24.22"/>
                    <measurement group_id="O4" value="2.2" spread="21.47"/>
                    <measurement group_id="O5" value="-2.8" spread="22.78"/>
                    <measurement group_id="O6" value="1.1" spread="19.21"/>
                    <measurement group_id="O7" value="2.8" spread="22.22"/>
                    <measurement group_id="O8" value="2.4" spread="20.69"/>
                    <measurement group_id="O9" value="-2.5" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Emotional Functioning</title>
        <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
        <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Emotional Functioning</title>
          <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="42"/>
                    <count group_id="O8" value="42"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="14.28"/>
                    <measurement group_id="O2" value="71.2" spread="18.51"/>
                    <measurement group_id="O3" value="77.4" spread="17.73"/>
                    <measurement group_id="O4" value="74.4" spread="29.50"/>
                    <measurement group_id="O5" value="71.1" spread="18.86"/>
                    <measurement group_id="O6" value="76.1" spread="23.54"/>
                    <measurement group_id="O7" value="75.8" spread="17.15"/>
                    <measurement group_id="O8" value="74.0" spread="23.87"/>
                    <measurement group_id="O9" value="79.6" spread="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="39"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="11.48"/>
                    <measurement group_id="O2" value="-4.2" spread="12.05"/>
                    <measurement group_id="O3" value="-0.8" spread="13.67"/>
                    <measurement group_id="O4" value="2.4" spread="11.52"/>
                    <measurement group_id="O5" value="4.4" spread="18.33"/>
                    <measurement group_id="O6" value="4.4" spread="6.19"/>
                    <measurement group_id="O7" value="2.4" spread="14.80"/>
                    <measurement group_id="O8" value="1.2" spread="10.47"/>
                    <measurement group_id="O9" value="-1.4" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="37"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="11.36"/>
                    <measurement group_id="O2" value="-4.9" spread="12.03"/>
                    <measurement group_id="O3" value="2.8" spread="13.18"/>
                    <measurement group_id="O4" value="3.8" spread="16.53"/>
                    <measurement group_id="O5" value="5.6" spread="13.24"/>
                    <measurement group_id="O6" value="-1.2" spread="14.93"/>
                    <measurement group_id="O7" value="3.6" spread="12.35"/>
                    <measurement group_id="O8" value="-0.6" spread="14.73"/>
                    <measurement group_id="O9" value="-1.9" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="39"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="17.63"/>
                    <measurement group_id="O2" value="-8.3" spread="22.19"/>
                    <measurement group_id="O3" value="-9.1" spread="18.43"/>
                    <measurement group_id="O4" value="2.4" spread="32.26"/>
                    <measurement group_id="O5" value="1.1" spread="15.06"/>
                    <measurement group_id="O6" value="-3.3" spread="14.36"/>
                    <measurement group_id="O7" value="-1.7" spread="17.12"/>
                    <measurement group_id="O8" value="-2.8" spread="23.76"/>
                    <measurement group_id="O9" value="-2.3" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="21.44"/>
                    <measurement group_id="O2" value="-6.9" spread="15.00"/>
                    <measurement group_id="O3" value="7.4" spread="17.40"/>
                    <measurement group_id="O4" value="5.0" spread="18.51"/>
                    <measurement group_id="O5" value="0.0" spread="7.11"/>
                    <measurement group_id="O6" value="6.7" spread="21.45"/>
                    <measurement group_id="O7" value="4.2" spread="15.98"/>
                    <measurement group_id="O8" value="1.0" spread="18.78"/>
                    <measurement group_id="O9" value="3.9" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Social Functioning</title>
        <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
        <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Social Functioning</title>
          <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="42"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" spread="19.21"/>
                    <measurement group_id="O2" value="51.3" spread="22.53"/>
                    <measurement group_id="O3" value="36.5" spread="21.18"/>
                    <measurement group_id="O4" value="63.5" spread="26.17"/>
                    <measurement group_id="O5" value="48.5" spread="19.95"/>
                    <measurement group_id="O6" value="55.7" spread="26.80"/>
                    <measurement group_id="O7" value="49.7" spread="23.13"/>
                    <measurement group_id="O8" value="56.9" spread="25.22"/>
                    <measurement group_id="O9" value="51.9" spread="25.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="13.49"/>
                    <measurement group_id="O2" value="2.1" spread="23.61"/>
                    <measurement group_id="O3" value="29.6" spread="23.67"/>
                    <measurement group_id="O4" value="-2.6" spread="12.49"/>
                    <measurement group_id="O5" value="-0.7" spread="21.91"/>
                    <measurement group_id="O6" value="8.5" spread="15.66"/>
                    <measurement group_id="O7" value="9.6" spread="23.78"/>
                    <measurement group_id="O8" value="2.8" spread="17.67"/>
                    <measurement group_id="O9" value="5.0" spread="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="15.51"/>
                    <measurement group_id="O2" value="-2.5" spread="26.05"/>
                    <measurement group_id="O3" value="22.8" spread="18.14"/>
                    <measurement group_id="O4" value="-1.5" spread="24.50"/>
                    <measurement group_id="O5" value="2.6" spread="23.95"/>
                    <measurement group_id="O6" value="4.8" spread="19.89"/>
                    <measurement group_id="O7" value="8.7" spread="21.19"/>
                    <measurement group_id="O8" value="0.4" spread="23.07"/>
                    <measurement group_id="O9" value="-1.2" spread="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="21.71"/>
                    <measurement group_id="O2" value="2.1" spread="26.14"/>
                    <measurement group_id="O3" value="17.8" spread="27.89"/>
                    <measurement group_id="O4" value="-5.6" spread="26.73"/>
                    <measurement group_id="O5" value="1.5" spread="30.10"/>
                    <measurement group_id="O6" value="5.7" spread="15.38"/>
                    <measurement group_id="O7" value="6.9" spread="27.25"/>
                    <measurement group_id="O8" value="0.8" spread="22.95"/>
                    <measurement group_id="O9" value="-0.6" spread="18.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="24.27"/>
                    <measurement group_id="O2" value="-5.1" spread="20.41"/>
                    <measurement group_id="O3" value="25.3" spread="21.73"/>
                    <measurement group_id="O4" value="-4.2" spread="28.43"/>
                    <measurement group_id="O5" value="-4.2" spread="25.42"/>
                    <measurement group_id="O6" value="11.9" spread="21.91"/>
                    <measurement group_id="O7" value="7.2" spread="26.36"/>
                    <measurement group_id="O8" value="0.5" spread="24.15"/>
                    <measurement group_id="O9" value="-0.5" spread="19.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Treatment Burden</title>
        <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
        <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Treatment Burden</title>
          <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="33"/>
                    <count group_id="O9" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" spread="25.56"/>
                    <measurement group_id="O2" value="68.9" spread="26.09"/>
                    <measurement group_id="O3" value="64.3" spread="29.29"/>
                    <measurement group_id="O4" value="73.1" spread="18.63"/>
                    <measurement group_id="O5" value="56.4" spread="27.76"/>
                    <measurement group_id="O6" value="54.5" spread="27.42"/>
                    <measurement group_id="O7" value="62.6" spread="27.39"/>
                    <measurement group_id="O8" value="65.7" spread="24.75"/>
                    <measurement group_id="O9" value="64.6" spread="30.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="19.46"/>
                    <measurement group_id="O2" value="-8.6" spread="29.28"/>
                    <measurement group_id="O3" value="0.0" spread="15.71"/>
                    <measurement group_id="O4" value="-9.3" spread="17.62"/>
                    <measurement group_id="O5" value="4.3" spread="14.01"/>
                    <measurement group_id="O6" value="4.0" spread="7.49"/>
                    <measurement group_id="O7" value="1.0" spread="16.04"/>
                    <measurement group_id="O8" value="-4.5" spread="19.73"/>
                    <measurement group_id="O9" value="-2.6" spread="19.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="28.03"/>
                    <measurement group_id="O2" value="-8.3" spread="27.70"/>
                    <measurement group_id="O3" value="8.3" spread="30.14"/>
                    <measurement group_id="O4" value="-10.0" spread="22.50"/>
                    <measurement group_id="O5" value="1.9" spread="13.26"/>
                    <measurement group_id="O6" value="-3.7" spread="25.46"/>
                    <measurement group_id="O7" value="-0.4" spread="24.26"/>
                    <measurement group_id="O8" value="-7.4" spread="24.27"/>
                    <measurement group_id="O9" value="-5.1" spread="25.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="21.81"/>
                    <measurement group_id="O2" value="-8.6" spread="31.32"/>
                    <measurement group_id="O3" value="-10.1" spread="16.07"/>
                    <measurement group_id="O4" value="-14.8" spread="23.37"/>
                    <measurement group_id="O5" value="6.8" spread="26.66"/>
                    <measurement group_id="O6" value="1.0" spread="9.23"/>
                    <measurement group_id="O7" value="-2.9" spread="22.92"/>
                    <measurement group_id="O8" value="-7.6" spread="22.83"/>
                    <measurement group_id="O9" value="-3.0" spread="30.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="26"/>
                    <count group_id="O8" value="24"/>
                    <count group_id="O9" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="26.19"/>
                    <measurement group_id="O2" value="-3.7" spread="31.92"/>
                    <measurement group_id="O3" value="0.0" spread="13.28"/>
                    <measurement group_id="O4" value="-4.2" spread="24.44"/>
                    <measurement group_id="O5" value="0.0" spread="17.37"/>
                    <measurement group_id="O6" value="12.7" spread="11.88"/>
                    <measurement group_id="O7" value="0.4" spread="18.72"/>
                    <measurement group_id="O8" value="0.9" spread="25.15"/>
                    <measurement group_id="O9" value="-5.1" spread="18.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Health Perceptions</title>
        <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
        <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Health Perceptions</title>
          <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="42"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="17.83"/>
                    <measurement group_id="O2" value="35.3" spread="19.29"/>
                    <measurement group_id="O3" value="33.1" spread="20.26"/>
                    <measurement group_id="O4" value="41.1" spread="27.83"/>
                    <measurement group_id="O5" value="39.4" spread="21.70"/>
                    <measurement group_id="O6" value="40.0" spread="20.70"/>
                    <measurement group_id="O7" value="37.7" spread="19.91"/>
                    <measurement group_id="O8" value="38.9" spread="22.52"/>
                    <measurement group_id="O9" value="41.7" spread="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="23.28"/>
                    <measurement group_id="O2" value="4.9" spread="20.24"/>
                    <measurement group_id="O3" value="10.0" spread="11.87"/>
                    <measurement group_id="O4" value="-2.4" spread="13.25"/>
                    <measurement group_id="O5" value="5.6" spread="13.24"/>
                    <measurement group_id="O6" value="5.6" spread="15.96"/>
                    <measurement group_id="O7" value="7.4" spread="16.52"/>
                    <measurement group_id="O8" value="2.6" spread="16.50"/>
                    <measurement group_id="O9" value="0.0" spread="16.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="26.54"/>
                    <measurement group_id="O2" value="4.9" spread="20.24"/>
                    <measurement group_id="O3" value="12.8" spread="16.26"/>
                    <measurement group_id="O4" value="3.8" spread="19.73"/>
                    <measurement group_id="O5" value="-1.1" spread="18.06"/>
                    <measurement group_id="O6" value="-1.8" spread="26.19"/>
                    <measurement group_id="O7" value="5.3" spread="21.19"/>
                    <measurement group_id="O8" value="2.1" spread="22.02"/>
                    <measurement group_id="O9" value="3.1" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="25.35"/>
                    <measurement group_id="O2" value="0.7" spread="17.93"/>
                    <measurement group_id="O3" value="-2.5" spread="15.28"/>
                    <measurement group_id="O4" value="-3.6" spread="23.51"/>
                    <measurement group_id="O5" value="1.1" spread="23.12"/>
                    <measurement group_id="O6" value="-0.6" spread="23.46"/>
                    <measurement group_id="O7" value="-1.4" spread="21.43"/>
                    <measurement group_id="O8" value="-1.2" spread="21.53"/>
                    <measurement group_id="O9" value="1.6" spread="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="13.99"/>
                    <measurement group_id="O2" value="0.0" spread="21.32"/>
                    <measurement group_id="O3" value="14.4" spread="19.72"/>
                    <measurement group_id="O4" value="6.7" spread="17.91"/>
                    <measurement group_id="O5" value="-1.4" spread="11.70"/>
                    <measurement group_id="O6" value="9.2" spread="14.93"/>
                    <measurement group_id="O7" value="7.4" spread="16.30"/>
                    <measurement group_id="O8" value="4.9" spread="18.31"/>
                    <measurement group_id="O9" value="0.9" spread="19.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Respiratory Symptoms</title>
        <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
        <time_frame>Baseline, Visit 102 (Day 8), Visit 103 (Day 29), End of Treatment (Day 113) and Visit 202 (Day 169)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A (3 Capsules o.d.): TIP</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O2">
            <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
            <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O3">
            <title>Cohort B (5 Capsules o.d.): TIP</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O4">
            <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
            <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O5">
            <title>Cohort C (4 Capsules b.i.d.): TIP</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
          </group>
          <group group_id="O6">
            <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
            <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
          </group>
          <group group_id="O7">
            <title>Pooled TIP</title>
            <description>Pooled Tobramycin inhalation powder (TIP): For efficacy analysis, subjects assigned to TIP groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O8">
            <title>Pooled TIP/PBO</title>
            <description>Pooled Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical: For efficacy analysis, subjects assigned to TIP/PBO groups were pooled across the 3 cohorts.</description>
          </group>
          <group group_id="O9">
            <title>Pooled PBO</title>
            <description>Pooled inhaled placebo (PBO): For efficacy analysis, subjects assigned to Placebo groups were pooled across the 3 cohorts, as the number of placebo capsules was not expected to impact the efficacy assessments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Respiratory Symptoms</title>
          <description>The QoL-B consists of 37 items across 8 domains: Physical Functioning (PF), Role Functioning (RF), Vitality, Emotional Function (EF), Social Functioning (SF), Treatment Burden (TB), Health Perception (HP) and Respiratory Symptoms (RS). Each of the 37 items is scored from 1 to 4, and each of the 8 scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HRQoL. A total score is not calculated since functioning can vary greatly from one domain to another. Only descriptive analysis performed.</description>
          <population>Full Analysis Set</population>
          <units>Score on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="43"/>
                    <count group_id="O8" value="42"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" spread="13.05"/>
                    <measurement group_id="O2" value="53.8" spread="18.12"/>
                    <measurement group_id="O3" value="56.8" spread="17.63"/>
                    <measurement group_id="O4" value="55.9" spread="21.69"/>
                    <measurement group_id="O5" value="52.3" spread="22.39"/>
                    <measurement group_id="O6" value="61.9" spread="13.31"/>
                    <measurement group_id="O7" value="55.0" spread="17.98"/>
                    <measurement group_id="O8" value="57.4" spread="17.83"/>
                    <measurement group_id="O9" value="53.8" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="6.83"/>
                    <measurement group_id="O2" value="6.5" spread="14.66"/>
                    <measurement group_id="O3" value="13.9" spread="16.12"/>
                    <measurement group_id="O4" value="3.3" spread="9.99"/>
                    <measurement group_id="O5" value="9.8" spread="12.30"/>
                    <measurement group_id="O6" value="-0.6" spread="16.20"/>
                    <measurement group_id="O7" value="11.2" spread="12.05"/>
                    <measurement group_id="O8" value="2.8" spread="13.85"/>
                    <measurement group_id="O9" value="1.0" spread="12.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="39"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="11.94"/>
                    <measurement group_id="O2" value="0.6" spread="19.97"/>
                    <measurement group_id="O3" value="6.3" spread="24.57"/>
                    <measurement group_id="O4" value="3.6" spread="14.69"/>
                    <measurement group_id="O5" value="6.9" spread="22.57"/>
                    <measurement group_id="O6" value="-5.7" spread="25.58"/>
                    <measurement group_id="O7" value="6.8" spread="19.65"/>
                    <measurement group_id="O8" value="-0.7" spread="20.58"/>
                    <measurement group_id="O9" value="2.3" spread="13.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at EoT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="40"/>
                    <count group_id="O8" value="41"/>
                    <count group_id="O9" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="11.21"/>
                    <measurement group_id="O2" value="4.1" spread="15.65"/>
                    <measurement group_id="O3" value="1.9" spread="18.52"/>
                    <measurement group_id="O4" value="-0.6" spread="20.73"/>
                    <measurement group_id="O5" value="6.7" spread="16.52"/>
                    <measurement group_id="O6" value="-6.5" spread="26.18"/>
                    <measurement group_id="O7" value="2.9" spread="15.58"/>
                    <measurement group_id="O8" value="-1.4" spread="21.59"/>
                    <measurement group_id="O9" value="4.0" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="11.76"/>
                    <measurement group_id="O2" value="0.9" spread="16.42"/>
                    <measurement group_id="O3" value="10.7" spread="8.63"/>
                    <measurement group_id="O4" value="-2.7" spread="24.33"/>
                    <measurement group_id="O5" value="5.6" spread="16.53"/>
                    <measurement group_id="O6" value="10.7" spread="12.52"/>
                    <measurement group_id="O7" value="7.6" spread="12.76"/>
                    <measurement group_id="O8" value="2.8" spread="18.57"/>
                    <measurement group_id="O9" value="1.6" spread="19.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study drug treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 134 days.</time_frame>
      <desc>Any sign or symptom that occurs during study treatment plus the 30 days post treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A (3 Capsules o.d.): TIP</title>
          <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="E2">
          <title>Cohort A (3 Capsules o.d.): TIP/PBO</title>
          <description>Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="E3">
          <title>Cohort A (3 Capsules o.d.): PBO</title>
          <description>Cohort A (3 capsules o.d.): Inhaled placebo (PBO)</description>
        </group>
        <group group_id="E4">
          <title>Cohort B (5 Capsules o.d.): TIP</title>
          <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="E5">
          <title>Cohort B (5 Capsules o.d.): TIP/PBO</title>
          <description>Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="E6">
          <title>Cohort B (5 Capsules o.d.): PBO</title>
          <description>Cohort B (5 capsules o.d.): inhaled placebo (PBO)</description>
        </group>
        <group group_id="E7">
          <title>Cohort C:4 Capsules b.i.d. TIP</title>
          <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)</description>
        </group>
        <group group_id="E8">
          <title>Cohort C (4 Capsules b.i.d.): TIP/PBO</title>
          <description>Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical</description>
        </group>
        <group group_id="E9">
          <title>Cohort C (4 Capsules b.i.d.): PBO</title>
          <description>Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sputum purulent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Airway complication of anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypobarism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood electrolytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eosinophil count abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Forced vital capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sputum abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urine protein/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea paroxysmal nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Increased viscosity of bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Novartis decided to close the recruitment of new subjects into this study earlier than scheduled. The early recruitment halt of the study was not due to safety or lack of efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

